
CytoDyn to Prepare a Phase 3 Protocol to Submit to the FDA for a Three-Arm Comparative and Combination Trial of Leronlimab and Remdesivir
VANCOUVER, Washington, May 18, 2020 — Three arms of this trial will be leronlimab, remdesivir, and leronlimab + remdesivir CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab (PRO 140), […]